Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Allergan closes $125m Oculeve buy
Allergan said it closed its purchase of dry eye disease device developer Oculeve for $125 million in up-front payments in addition to unspecified commercialization milestones.
South San Francisco-based Oculeve is developing a product called OD-01, a non-invasive nasal neurostimulation device designed to increase tear production in patients with dry eye disease, Allergan said. Oculeve has completed 4 clinical trials of OD-01 to date. Read more
2. Helius & US Army launch neuromod device trial
Helius Medical said it and the U.S. Army Medical Research and Material Command have launched a phase 3 clinical trial of Helius’ portable neuromodulation stimulator.
The PoNS unit is designed to treat balance disorder in patients with mild-to-moderate traumatic brain injury, the Newtown, Pa.-based company said. Read more
1. DexCom inks partnership with Google Life Sciences
Dexcom Inc. said it signed a partnership deal with the life sciences team at Google to jointly develop continuous glucose monitoring products.
The new partnership will bring together Google’s miniaturized electronics platform and DexCom’s sensor technology, and looks to develop next-generation CGM devices that will be less expensive than existing technologies, San Diego, Calif.-based DexCom said. Read more
The post MassDevice.com +3 | The top 3 medtech stories for August 11, 2015 appeared first on MassDevice.
from MassDevice http://ift.tt/1IDRsEZ
Cap comentari:
Publica un comentari a l'entrada